2025年7月9日,默沙东(MSD)发布公告称,将通过子公司以每股美国存托股票(American Depository Share, ADS)107美金、总价约为100亿美金的价格收购总部位于英国伦敦的Verona Pharma。通过此次收购,MSD获得了Verona的上市产品Ohtuvayre®,该产品于2024年6月获美国FDA批准上市,用于成人慢性阻塞性肺病(COPD)的维持治疗。除此之外,...
Source Link2025年7月9日,默沙东(MSD)发布公告称,将通过子公司以每股美国存托股票(American Depository Share, ADS)107美金、总价约为100亿美金的价格收购总部位于英国伦敦的Verona Pharma。通过此次收购,MSD获得了Verona的上市产品Ohtuvayre®,该产品于2024年6月获美国FDA批准上市,用于成人慢性阻塞性肺病(COPD)的维持治疗。除此之外,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.